Clinical Trial Update: Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine [Phase 1]

View source ↗

Summary

Phase 1 safety study of GSK2231395A, a vaccine candidate from GlaxoSmithKline, for Haemophilus influenzae and Streptococcus pneumoniae, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Infection
• Streptococcus Pneumoniae Infection

Drugs mentioned

• GSK2231395A

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae, Streptococcus Pneumoniae | Phase 1 | Status: TERMINATED